Alegaon S G, Alagawadi K R, Dadwe D H
Department of Pharmaceutical Chemistry, KLE University's College of Pharmacy, Belgaum, Karnataka, India.
Drug Res (Stuttg). 2014 Oct;64(10):553-8. doi: 10.1055/s-0033-1363976. Epub 2014 Jan 20.
Novel 3,5-diaryl-4,5-dihydro-1H-pyrazole derivatives were efficiently synthesized and evaluated for their in vitro antitubercular activity against Mycobacterium tuberculosis H37Rv (MTB). The chemical structures of the compound were elucidated by elemental analysis, FTIR, (1)H NMR, and mass spectral data. Most of the title compounds have exhibited significant antitubercular activity. Compounds 4g, 4h, 4l, 4n and 4o showed pronounced antitubercular activity comparable to the reference isoniazid, whereas, compounds 4a, 4c, 4j, 4k, and 4p displayed good antitubercular activity. 5-(4-chlorophenyl)-4,5-dihydro-3-p-tolylpyrazol-1-yl-(6-methylimidazo[2,1-b]thiazol-5-yl)methanone (4g) was found to be the most promising compound with MIC values of 0.39 µg/ml.
新型3,5-二芳基-4,5-二氢-1H-吡唑衍生物被高效合成,并对其针对结核分枝杆菌H37Rv(MTB)的体外抗结核活性进行了评估。通过元素分析、傅里叶变换红外光谱(FTIR)、核磁共振氢谱(¹H NMR)和质谱数据阐明了化合物的化学结构。大多数标题化合物都表现出显著的抗结核活性。化合物4g、4h、4l、4n和4o表现出与参比异烟肼相当的显著抗结核活性,而化合物4a、4c、4j、4k和4p表现出良好的抗结核活性。5-(4-氯苯基)-4,5-二氢-3-对甲苯基吡唑-1-基-(6-甲基咪唑并[2,1-b]噻唑-5-基)甲酮(4g)被发现是最有前景的化合物,其最低抑菌浓度(MIC)值为0.39μg/ml。